Doctors develop new light-based treatment for rare eye infection
Tired of too many ads? go ad free now
This infection is caused by amoeba found in places like water and soil. According to the study, it mostly affects people who wear contact lenses or come into contact with dirty water, such as those working on farms or using tap water to clean their lenses.
Doctors tested a new light-based treatment called photodynamic therapy (PDAT-RB) and found it promising. The antimicrobial treatment uses a special dye called rose bengal, which is activated by light to produce powerful molecules that kill the infection.
This, in turn, helped reduce inflammation in the eye. Rose bengal is a reddish-pink dye used in the diagnosis of eye conditions, which turned out to act as an effective photosensitising agent.
Published in the United Kingdom-based Journal of Ophthalmic Inflammation and Infection, the study states that the most common cause of this disease is exposure of the eyes to contaminated water, especially in agricultural fields or washing contact lenses with tap water.
An estimated 30-40% of patients suffering from AK require corneal transplantation, known as keratoplasty, on average. Despite that, many do not regain good visual acuity and require additional surgery.
This study included 14 patients with AK infection. At first, they were given regular medicines to treat the infection. Then they received the new light-based PDAT treatment twice a week. The doctors used a solution with 0.1% rose bengal dye as part of the therapy.
Tired of too many ads? go ad free now
Doctors found that the treatment with the PDAT-RB reduced the need for corneal transplantation in 72% of the total patients with bacterial keratitis (inflammation of the cornea). Moreover, the infection was cleared in about 86% of patients within two to five months after the treatment.
While most patients were suffering from almost complete vision loss before the treatment, only two of the total patients in the study required a corneal transplant to repair the damaged part.
Although their vision improved after PDAT-RB therapy, they still had poor sight. On average, their vision went from total blindness to being able to see large objects or movement.
Dr Gowtham Lakshminarayan, a research assistant scientist involved in the study, explained that the treatment works by creating powerful chemicals that destroy the harmful organisms in the eye.
"The study suggests that if this treatment is used early, it can be a helpful and less-invasive (non-surgical) option to manage a severe eye infection that is usually hard to treat with regular medicines. The new treatment also shows that rose bengal is an effective photosensitiser and that early intervention with PDAT-RB treatment can yield promising results in the AK eye infection," he added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
29 minutes ago
- Time of India
Trump administration asks US Supreme Court to allow NIH diversity-related cuts
New York: Donald Trump's administration asked the U.S. Supreme Court on Thursday to allow the government to proceed with sweeping cuts to National Institutes of Health grants as part of the Republican president's crackdown on diversity initiatives. The Justice Department asked the justices to lift Boston-based U.S. District Judge William Young's June ruling that halted the plan as a violation of federal law and required the government to reinstate access to the grant funds. The judge acted in a legal challenge by researchers and 16 U.S. states, led by Democratic-governed Massachusetts. The NIH is the world's largest funder of biomedical research. The cuts are part of Trump's wide-ranging actions to reshape the U.S. government, slash federal spending and end government support for diversity, equity and inclusion programs and transgender healthcare. The administration repeatedly has sought the Supreme Court's intervention to allow implementation of Trump policies impeded by lower courts. The Supreme Court, which has a 6-3 conservative majority, has sided with the administration in almost every case that it has been called upon to review since Trump returned to the presidency in January. In June, dozens of scientists, researchers and other NIH employees signed an open letter criticizing the agency's actions and spending cuts under Trump that they said politicize research and "harm the health of Americans and people across the globe." Young's ruling came in two lawsuits challenging the cuts. One was filed by the American Public Health Association, individual researchers and other plaintiffs who called the cuts an "ongoing ideological purge" of projects with a purported connection to gender identity, DEI "or other vague, now-forbidden language." The other was filed by the states, most of them Democratic-led. Young, an appointee of Republican former President Ronald Reagan, invalidated the grant terminations in June. The judge wrote that every new administration is entitled to make policy changes but that these must be reasonable and reasonably explained. Instead, according to the judge, the steps taken by Trump administration officials were "breathtakingly arbitrary and capricious," violating a federal law governing the actions of agencies. Young criticized administration officials for not offering any definition of DEI while disparaging studies they deemed low-value and unscientific that the officials claimed were used to unlawfully discriminate on the basis of race and other protected characteristics. "There is not a shred of evidence supporting any of these statements in the record," Young wrote. Many U.S. conservatives contend that DEI policies discriminate against white people. The Boston-based 1st U.S. Circuit Court of Appeals on July 18 denied the administration's request to put Young's decision on hold. The administration has argued that the litigation should have been brought in a different judicial body, the Washington-based Court of Federal Claims, which specializes in money damages claims against the U.S. government. That reasoning was also the basis for the Supreme Court's decision in April that let Trump's administration proceed with millions of dollars of cuts to teacher training grants also targeted under the DEI crackdown.
Mint
an hour ago
- Mint
India has the potential to be a global lab for scalable longevity solutions: Accel's Prashanth Prakash
Bengaluru-based wellness startup Biopeak had raised $3.5 million recently in a funding round led by Prashanth Prakash, founding partner of Accel Partners, that also saw participation from Manipal Group's Ranjan Pai through his investment vehicle Claypond Capital and Zerodha's Nikhil Kamath and Nithin Kamath. In this exclusive interview, Prakash talks about longevity as a concept and its importance in future. Excerpts: Hello Prashanth, what was the thought process behind this investment decision? The timing of this investment is deeply intentional. We are at a unique intersection in human health where diagnostics, artificial intelligence, and longevity science are converging with extraordinary speed. Biopeak is building an integrated, precision health system grounded in global science but tailored to the unique biological, environmental, and lifestyle factors of the Indian population. This is not just a business bet—it's a belief that India will lead the world in next-generation healthcare. The thought process was simple: medicine is shifting from reactive to predictive and preventive, and Biopeak is among the few platforms architecting that future in a scalable, scientifically grounded way. It will enable us to plot with unprecedented detail personalised health trajectories for a specific individual using multi-dimensional data collection, integration, and prediction. The focus on deeply personalised healthcare is going to be huge in the future. Right? The transition from universal averages to personalised insights will represent a revolution in how we detect, predict, prevent adverse events and build resilience reserves. This new model of Biology and AI-led medicine is an exciting paradigm for the future of healthcare in our country that investors are excited to back. What's your definition of longevity? Longevity, for us, is not merely about extending the lifespan but expanding the healthspan. Ensuring more years that are healthy, vital, and productive is more crucial. In the Indian context, this requires a unique balance: respect for traditional knowledge systems, alignment with evolving regulatory frameworks, and deep reliance on evidence-based science. We're combining cutting-edge diagnostics—from microbiome and metabolomics to imaging and functional genomics—with culturally compatible interventions and a powerful AI layer. Longevity for us in India means democratising access to health optimisation—life partnerships between human intelligence and machine precision, rooted in science, ethics, and scale. In ancient civilizations including India, people were said to have lived for a much longer span of time. How do you relate that to the work Biopeak is doing and the results it is hoping to achieve? While environmental and societal contexts have changed drastically, ancient systems often emphasised internal balance, rhythm with nature, and preventative health —all are core principles in today's longevity science. At Biopeak, we're not romanticising the past—we're modelling it. Using symbolic and generative AI frameworks, we're integrating timeless health principles with modern biological data to predict individual responses to pharmaceuticals, nutraceuticals, and lifestyle interventions. It's not about replicating ancient lifespans—it's about reclaiming biological potential by harmonising past wisdom with today's precision tools. Do you think longevity as a concept can be realistically spread to all sections of society? Or will it remain only an aspiration of the well-heeled? Longevity must not become a luxury. With AI at the core of Biopeak's platform, we can rapidly model and scale health solutions based on outcomes from higher-touch cases to broader population needs. What starts with the few can be democratised for the many through intelligent design, efficient diagnostics, and continuous learning from diverse cohorts. India has the potential to be a global lab for scalable longevity solutions—not by diluting science but by deploying it with cultural and economic sensitivity. Through our own longitudinal data leveraging interdisciplinary collaboration (Longevity India, an initiative of the Indian Institute of Science), we aim to identify markers of organ system malfunction before pathology sets in so that we can implement a health management program which will extend healthspan and improve the quality of life for the ageing population across all sections of society. At the core of Biopeak's offering, I believe, is a diagnostic system that includes tests like organic acid profiling, microbiome mapping, salivary cortisol rhythms, and whole-exome functional genomics. These are paired with imaging tools such as MRI, CT, and ECHO, as well as tissue-level screenings that examine markers like mineral levels, toxin load, and oxidative stress. Does this make Biopeak a unique company in the world? Yes, Biopeak is unique both in its scientific architecture and its population focus. It combines multiple high-resolution diagnostic modalities—molecular, functional, and structural—into a unified health intelligence platform. Each individual is paired with a biologist and clinician, and guided through a dynamic health roadmap. What further sets it apart is its South Asia-centric design, which considers the genetic, dietary, cultural, and environmental nuances of this region. Supported by research from institutions like IISc and informed by global best practices, Biopeak is not just another health company—it's a systems-level rethink of what human health can be in the 21st century. What's Medicine 4.0? What does it look to solve? What are its basic principles? Medicine 4.0 is the natural evolution of healthcare in the age of AI and high-resolution biology. It's defined by its longitudinal view of health, multisystem diagnostics, real-time feedback loops, and personalised intervention frameworks. It's not about treating symptoms—it's about continuously adapting to the evolving biology of the individual. This approach integrates international technologies, leverages big data with small, precise insights, and focuses on outcomes over time rather than episodic care. In short, it's predictive, participatory, personalised, and preventive. What do you think are the key pillars of the Medicine 4.0 framework as far as BioPeak is concerned? Biopeak leverages data from modern genomics, metabolomics, lipidomics, and metagenomics analytics to provide a molecular view of an individual's unique biology. This integration identifies systemic equilibrium for identifying subtle imbalances and hidden dysfunctions long before symptoms arise. From DXA scans for bone density to functional MRIs and real-time metabolic imaging, Biopeak employs cutting-edge tools that visualise internal systems and structural health markers. Using a hybrid AI approach, combining symbolic AI (for precise, rule-based interpretations) and generative AI (for pattern recognition and predictive modelling), Biopeak can detect complex biological interrelations and generate personalised health insights. What do you think are the limitations of the current health systems worldwide and in India? Globally and in India, health systems remain largely reactive, fragmented, and oriented around acute interventions rather than long-term prevention. There's a heavy focus on managing disease rather than predicting and reversing the conditions that lead to it. What's missing is a systems view—an integration of diagnostics, therapeutics, and lifestyle within a cohesive, continuously updating framework. People are treated as conditions, not as dynamic ecosystems. Long-term biological consequences of current choices are rarely factored into care. The foundation of Medicine 2.0 was built on population averages, with protocols and interventions developed based on data from extensive observational and interventional studies. While this approach helped standardise treatments, it does not account for individual variability. Each person's genetic framework, metabolism, lifestyle, and environment interactions are unique, making the n=1 (individual-first) model essential for true health optimisation. Biopeak is solving for precisely this: unifying the fragmented landscape into an intelligent, longitudinal system centred around the individual.
New Indian Express
2 hours ago
- New Indian Express
Hyderabad startup reverses chronic liver failure in animal trials
HYDERABAD: A Hyderabad-based startup, Tulsi Therapeutics, has demonstrated the complete reversal of chronic liver failure in animal trials using an innovative stem cell-exosome therapy. Conducted on rats, the preclinical study showed 100% liver fibrosis reversal and zero mortality among treated subjects, in stark contrast to the untreated group that saw only 14% reversal and 43% deaths. Tulsi-28X is a first-in-class regenerative biologic derived from Wharton's Jelly mesenchymal stem cells and their native exosomes, a combination never before tested in any animal model globally. Tulsi Therapeutics, incubated at ASPIRE-BioNEST, University of Hyderabad, developed the platform entirely in India over three years. Chronic liver failure accounts for nearly 20% of all liver-related deaths globally, with liver transplantation being the only treatment. Founder and CEO of Tulsi Therapeutics Dr Sairam Atluri said, 'There have been individual successes with stem cells and exosomes, but we combined them because they operate through different mechanisms. This combination maximised the biological outcome and marks a major milestone for India's biotech sector.' Looking ahead, the chief scientific officer said the next goal is to initiate human clinical trials in partnership with Nizam's Institute of Medical Sciences (NIMS), with groundwork expected to take up to two years. The results were presented at the AASLD 2024 Liver Conference in San Diego and have also been accepted for publication in the Journal of Regenerative Medicine.
